Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Nature Communications|May 13, 2021
Ultraviolet light-induced collagen degradation inhibits melanoma invasionTimothy Budden, Caroline Gaudy-Marqueste, Andrew Porter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Female Immunity Protects from Cutaneous Squamous Cell CarcinomaTimothy Budden, Caroline Gaudy-Marqueste, Sarah Craig, et al.
Oncotarget|January 20, 2018
A novel anti-CD146 antibody specifically targets cancer cells by internalizing the moleculeMarie Nollet, Jimmy Stalin, Anaïs Moyon, et al.
Acta Dermato-Venereologica|December 13, 2024
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre StudyLucille Vitek, Thomas Goronflot, Caroline Dutriaux, et al.
Nature Metabolism|April 27, 2026
Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasionTimothy Budden, Noah Palombo, Shilpa Gurung, et al.
The Oncologist|July 3, 2024
Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée)Perrine Rousset, Charlée Nardin, Eve Maubec, et al.
Human Molecular Genetics|August 20, 2004
Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathyClaire L Navarro, Annachiara De Sandre-Giovannoli, Rafaëlle Bernard, et al.
Cancer|December 8, 2024
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational studyIona Campo Le Brun, Séphane Dalle, Laurent Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
The Oncologist|May 18, 2024
Molecularly matched targeted therapy: a promising approach for refractory metastatic melanomaEmily Connell, Émilie Gerard, Bénédicte Oules, et al.
Pageof 7